84 results
Page 2 of 5
8-K
EX-10.2
ovg55s 42d1zh
1 Jul 16
Departure of Directors or Certain Officers
12:00am
8-K
EX-10.1
87pbvud36
27 Apr 15
Departure of Directors or Certain Officers
12:00am
8-K
EX-10.1
e9ue6 onri
31 Mar 15
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.2
oi5653rfu12udr0 pr
31 Mar 15
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.1
6bcepw1 kxn7q
24 Oct 14
Cellceutix Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable to 7-Days of Daptomycin
12:00am
8-K
EX-10.46
oe0o smm5fll2im
2 Sep 14
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
12:00am
8-K
EX-10.48
83fll3ucr74m4wm3cz
2 Sep 14
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
12:00am
8-K
EX-10.47
yq10ntnl
2 Sep 14
Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
12:00am
8-K
EX-10
kfkl5j9m3zf95g7b4p
28 Oct 13
Cellceutix Enters into New $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
8-K
EX-10
q54wg
28 Oct 13
Cellceutix Enters into New $20 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC
12:00am
S-3
EX-10
6b72rn qa8h4sa7i
22 Jan 13
Shelf registration
12:00am
S-3
EX-10
v67jytfsri03quzm
22 Jan 13
Shelf registration
12:00am
S-3
EX-10
i9nte1fp 6d
22 Jan 13
Shelf registration
12:00am
8-K
EX-10.39
wby y1lkhizg4o53rv
8 Jan 13
Termination of a Material Definitive Agreement
12:00am